GCG and metabolic syndrome: Furthermore, GLP-1 analogues, in contrast to DPP-4i, act on typical features associated with chronic GC excess, such as increased appetite, obesity, increased visceral fat mass, altered secretion of adipocytokines and dyslipidemia [20].